These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38516533)

  • 1. Antibiotic resistance of ESKAPE group-microorganisms in health institutions from Hermosillo and Ciudad Obregón, Sonora, México.
    Álvarez-Ainza ML; Fong-Coronado PA; Ruiz-Bustos E; Castillón-Campaña LG; Quintero-Reyes IE; Duarte-Zambrano LA; Bolado-Martínez E
    Front Cell Infect Microbiol; 2024; 14():1348093. PubMed ID: 38516533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health.
    Denissen J; Reyneke B; Waso-Reyneke M; Havenga B; Barnard T; Khan S; Khan W
    Int J Hyg Environ Health; 2022 Jul; 244():114006. PubMed ID: 35841823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Antimicrobial Resistance Levels of ESKAPE Microorganisms in a Peruvian IV-Level Hospital.
    Flores-Paredes W; Luque N; Albornoz R; Rojas N; Espinoza M; Pons MJ; Ruiz J
    Infect Chemother; 2021 Sep; 53(3):449-462. PubMed ID: 34508324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.
    Zhen X; Lundborg CS; Sun X; Hu X; Dong H
    Antimicrob Resist Infect Control; 2019; 8():137. PubMed ID: 31417673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
    Kharat AS; Makwana N; Nasser M; Gayen S; Yadav B; Kumar D; Veeraraghavan B; Mercier C
    Int J Antimicrob Agents; 2024 May; 63(5):107125. PubMed ID: 38431109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of community origin of major multidrug-resistant ESKAPE uropathogens in a paediatric population in South-East Gabon.
    Mouanga-Ndzime Y; Onanga R; Longo-Pendy NM; Bignoumba M; Bisseye C
    Antimicrob Resist Infect Control; 2023 May; 12(1):47. PubMed ID: 37173760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole Genome Sequencing of Extended Spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae Isolated from Hospitalized Patients in KwaZulu-Natal, South Africa.
    Founou RC; Founou LL; Allam M; Ismail A; Essack SY
    Sci Rep; 2019 Apr; 9(1):6266. PubMed ID: 31000772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal dispersion of Acinetobacter baumannii in an intensive care unit designed to patients COVID-19.
    Durán-Manuel EM; Cruz-Cruz C; Ibáñez-Cervantes G; Bravata-Alcantará JC; Sosa-Hernández O; Delgado-Balbuena L; León-García G; Cortés-Ortíz IA; Cureño-Díaz MA; Castro-Escarpulli G; Vélez-Reséndiz JM; Bello-López JM
    J Infect Dev Ctries; 2021 Jan; 15(1):58-68. PubMed ID: 33571146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of resistance profiles ESKAPE pathogens from 2010-2015 in a tertiary respiratory center in Romania.
    Peneş NO; Muntean AA; Moisoiu A; Muntean MM; Chirca A; Bogdan MA; Popa MI
    Rom J Morphol Embryol; 2017; 58(3):909-922. PubMed ID: 29250670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico.
    Llaca-Díaz JM; Mendoza-Olazarán S; Camacho-Ortiz A; Flores S; Garza-González E
    Chemotherapy; 2012; 58(6):475-81. PubMed ID: 23548324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.
    Miller WR; Arias CA
    Nat Rev Microbiol; 2024 Oct; 22(10):598-616. PubMed ID: 38831030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens.
    Saha U; Gondi R; Patil A; Saroj SD
    Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternatives for the treatment of infections caused by ESKAPE pathogens.
    da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
    J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Emergence of High Persistence upon Periodic Aminoglycoside Challenge in the ESKAPE Pathogens.
    Michiels JE; Van den Bergh B; Verstraeten N; Fauvart M; Michiels J
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4630-7. PubMed ID: 27185802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of ESKAPE Bacterial Pathogens at the Point of Care Using Isothermal DNA-Based Assays in a Portable Degas-Actuated Microfluidic Diagnostic Assay Platform.
    Renner LD; Zan J; Hu LI; Martinez M; Resto PJ; Siegel AC; Torres C; Hall SB; Slezak TR; Nguyen TH; Weibel DB
    Appl Environ Microbiol; 2017 Feb; 83(4):. PubMed ID: 27986722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESKAPE in China: epidemiology and characteristics of antibiotic resistance.
    Luo Q; Lu P; Chen Y; Shen P; Zheng B; Ji J; Ying C; Liu Z; Xiao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2317915. PubMed ID: 38356197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development.
    Yu H; Xu Y; Imani S; Zhao Z; Ullah S; Wang Q
    ACS Infect Dis; 2024 Jul; 10(7):2336-2355. PubMed ID: 38866389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmid profiles among some ESKAPE pathogens in a tertiary care centre in south India.
    Ragupathi NKD; Bakthavatchalam YD; Mathur P; Pragasam AK; Walia K; Ohri VC; Veeraraghavan B
    Indian J Med Res; 2019 Feb; 149(2):222-231. PubMed ID: 31219087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement and prediction of antimicrobial resistance in bloodstream infections by ESKAPE pathogens and Escherichia coli.
    De Socio GV; Rubbioni P; Botta D; Cenci E; Belati A; Paggi R; Pasticci MB; Mencacci A
    J Glob Antimicrob Resist; 2019 Dec; 19():154-160. PubMed ID: 31112804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acinetobacter baumannii: Pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline.
    Dehbanipour R; Ghalavand Z
    J Clin Pharm Ther; 2022 Nov; 47(11):1875-1884. PubMed ID: 36200470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.